Treatment consisted of oral decitabine 35 mg plus cedazuridine 100 mg on days 1–5 and venetoclax (variable doses of 100–400 mg, day 1 to 14, 28-day cycle). The primary outcomes were safety for the ...

In phase 1, 75% of patients had also received chemotherapy whereas only 31% had in phase 2. In the phase 1 portion of the trial, ARV-110 doses ranged from 35–700 mg QD or 210–420 mg BID. Based on ...

Thus, the recommended phase 2 dose was 600 µg of SHR-1501 + 120 mg of BCG. Grade 3 or worse treatment-related adverse events (TRAEs) were reported in 1 patient (12.5%) receiving SHR-1501 alone ...